{"name":"Kinevant Sciences GmbH","slug":"kinevant-sciences-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNRElIZHpKS1pIaUZUUFBxLTVRaHhqMWRrWWlxTlJHLVJTR0QxS0diOHJQZGpMUTlJaG5tR3F1Q0FkYl9nM283aGRveXRKWVpoX0FXV0hDMlFtMVRVLXVsSG5IRV9zY3EwTkc4NEttTGp1YUtBeGh3UjE0cEJmWFhNNVRIbEZPX2Y5S0tlN3BDVXg4U01lcWh2dUFlcXloaTFOczRfTXd0alZIZGdpRk9OYmtkbWNHR08zVG9SOHJCVm44ekdVR19GNXd1MkQtbDA?oc=5","date":"2025-11-21","type":"pipeline","source":"European Medical Journal","summary":"Targeted Therapy for Interstitial Lung Disease and the Role of Nerandomilast - European Medical Journal","headline":"Targeted Therapy for Interstitial Lung Disease and the Role of Nerandomilast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPazJwc25lRkQtay03aTlTak5ON0NOQklCVElXSHFTYldQV1VobFRpNGxGREFtWEd3Y3VYQVVaRTVUUVhUb2lwU1FNeWdwTFhYdWtDd1NoclhpM3dicFhfM2JpZC1pQkdYNnk5bGh2bU92U0R4VkFQQkFqeGlBaDdIaTQ2Tmt3QkNTLTYtQ1RLa216aU54ZU41U0draVRsMUZsSE9XLVBaMEdndXRZ?oc=5","date":"2024-12-03","type":"trial","source":"Fierce Biotech","summary":"Roivant spinout ends development of lung disease asset after phase 2 fail - Fierce Biotech","headline":"Roivant spinout ends development of lung disease asset after phase 2 fail","sentiment":"negative"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}